PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
August 20, 20250 citationsOpen Access

Figure 2 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

View Full Paper
SLSamantha I. LiangZQZoe QuandtSWSara Wienke

Key Points

  • Significant tumor fraction changes correlated with improved clinical outcomes in patients treated with immune checkpoint inhibitors.
  • Kaplan–Meier analysis showed a strong association between tumor fraction decrease and better rwPFS, with P-values highlight its significance.
  • Observational analysis using a real-world dataset identifies candidate thresholds for tumor fraction changes indicating treatment response.
  • These findings support potential biomarker development for personalized immunotherapy approaches in cancer management.

Abstract

A and B, Candidate thresholds for TF change indicating MR and nMR among the patients in whom either T0 or T1 were quantifiable (n = 459). A, Forest plot for various TF changes (B) Kaplan–Meier analysis of rwPFS by select candidate thresholds across the full dataset. Log-rank test between groups: 100% vs. any decrease, P P = 0.01; 100% decrease vs. 80% decrease, P = 0.04; 100% decrease vs. any increase, P P P

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Liang et al. (2025) studied this question.

synapsesocial.com/papers/68af55d8ad7bf08b1eadc776https://doi.org/10.1158/2767-9764.29948108
Ask AI
Helpful
Bookmark
Share
View Full Paper